Group 1: Company Overview - The company achieved a revenue of 72.11 million yuan in 2024, representing a year-on-year growth of 20.8%, while the net profit attributable to shareholders was -45.18 million yuan, a reduction in losses compared to the same period in 2023 [1] - In Q1 2025, the company reported a revenue of 16.42 million yuan, a year-on-year increase of 1.85%, with a net profit of -0.77 million yuan, marking a 37.01% reduction in losses compared to the previous year [1] - The company has not yet launched any new drugs, but its ophthalmic products are the core revenue source, continuously supporting new drug development [1] Group 2: Clinical Progress - The company's NL003 project, a recombinant human hepatocyte growth factor naked plasmid injection, has made significant progress, with both the ulcer group and resting pain group of the Phase III clinical trials completing unblinding [2] - The primary endpoint of the NL003 resting pain group showed a significant improvement over the placebo group, with a p-value of less than 0.0001, indicating statistical significance [2] - NL003 successfully passed registration inspection in September 2024, with its production process meeting GMP standards, establishing a stable and controllable production and quality management system [2] Group 3: Production and Commercialization - The company's biopharmaceutical industrialization project in Tongzhou, Beijing, has achieved important milestones, including the completion of municipal power capacity approval and design for various facilities [3] - The completion of this project is expected to significantly enhance the company's production capacity in the biopharmaceutical field, providing strong support for the commercialization of innovative drugs [3] - In October 2024, the company opened a branch in Shanghai, further facilitating its commercialization efforts [3] Group 4: Financial Forecast - The company forecasts revenues of 88 million yuan, 185 million yuan, and 371 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of -0.19, -0.01, and 0.30 yuan [4] - The current stock price corresponds to PE ratios of -114.7, -2402.2, and 70.6 times for the years 2025, 2026, and 2027 respectively, with an initial coverage rating of "buy" [4]

导读： 几乎所有生命科学相关从业者，都绕不开质粒提取这项工作。这篇文章旨在让你在质粒提取的过 程中不再"迷茫"。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 质粒提取工作，涉及从学生到科学家、从实验室到工厂、从基础研究到产业转化的几乎 所有生 命科学相关从业者 。 无论你是刚进实验室的研究生，还是在GMP车间里工作的工艺工程师，只要你在做分子层面的 工作，就绕不开这个 "看似简单但极其关键"的实验 。 小编整理了大量关于 质粒提取的"必考知识点 "，宝藏准备好了，收不收看你： 知识点目录： 插播福利 识别下方二维码 1、 一个合格质粒的组成要素 2、 如何阅读质粒图谱 3、 质粒提取原理详解 4、 实验室常用的质粒的提取方法 5、质粒提取的注意事项 6、提高质粒提取浓度低7大方法 7、质粒DNA的小量制备 8、19个质粒提取常见问题及解决方案 9、 质粒提取标准流程 10、质粒提取实验中 常见溶液的实用替代品 3 0秒参与有奖调研 抢价值3 9 9 9元的大奖 奖品预览： 小 米 背 包 5 0 只 、 时 尚 三 折 伞 5 0 只 ...

以下文章来源于源井生物 ，作者小源 源井生物 . CRISPR文库，想筛就筛 源井生物是一家专注于细胞基因编辑研发与生产的国际化高新技术企业，目前已为全球范围内超40个国 家的科研单位和工业客户提供基因编辑技术服务与相关产品。 "让基因编辑更简单"是源井的企业目 标，我们将以务实、高效、坦诚和守信的态度服务好每一位客户！ 倾情回馈抽奖活动 新老客户皆享好礼，下单即有惊喜！ 奖项 名额 奖品内容 特等奖 3名 SKG颈椎按摩仪K5-2尊贵版 源井定制背包 | | | 活动期间内，单笔订单实付满￥2000，即可参与抽奖一次，100%中奖！ 二等奖 8名 蕉下黑胶胶囊伞 三等奖 10名 实用桌面小风扇 参与奖 不限 平台会员月卡 · 一步搞定CRISPR筛选！ CRISPR文库质粒 ·覆盖度＞99% ·均一性＜10 Screening-ready Cell Pool 400 + ·覆盖度高达100% ·即买即用 从建库到生信数据分析，全都替你搞定！ 全流程整包服务 自由组合（DIY），搭建专属筛选体系！ ·全基因组Screening-ready Cell Pool 全场半价使用 ·功能筛选&NGS测序，低至 联系电 ...

"悟空"号国际合作组科研人员介绍，在宇宙线中，硼原子核主要是碳核、氧核等原初核素在传播过程中 和星际物质发生碰撞后产生的次级粒子，其能谱反映了宇宙线扩散传播过程的重要信息。 本报讯(记者蔡姝雯)记者近日从中国科学院紫金山天文台获悉，暗物质粒子探测卫星"悟空"号国际合作 组利用该卫星前8年观测数据，在国际上首次获得了TeV/n(高能物理中的能量单位，1TeV/n=1万亿电子 伏特/核子)能区最精确的次级宇宙线硼核能谱，并发现了能谱新结构。这一观测为修正宇宙线传播模型 提供了最新的观测依据。 宇宙线是来自外太空的高能粒子流，主要由各种质子、原子核、电子、高能伽马射线和中微子等组成。 宇宙线的起源和传播是物理和天文领域重要的前沿科学问题。 作为我国发射的第一颗用于空间高能粒子观测的天文卫星，"悟空"号的核心科学目标除了探测暗物质粒 子，还包括通过探测宇宙线核素粒子来研究宇宙线的加速和传播机制。 近年来，国际上的一些直接观测实验发现，宇宙线硼核能谱在百GeV/n以上能区存在变硬(即能谱指数增 大)的迹象，这意味着观测到了比理论预测更多的粒子，但因测量精度的限制，无法对此给出确切的探 测结果，也不能有效地检验现有的宇宙 ...

Investment Rating - The investment rating for the company is "Buy" with a first coverage [1]. Core Views - The company is positioned in the innovative gene therapy sector and is entering a harvest period with its products [4]. - The company reported a revenue of 72.11 million yuan in 2024, representing a growth of 20.80%, but incurred a net loss of 45.18 million yuan [4]. - The innovative drugs NL003 and NL005 are in advanced stages of clinical development, with NL003 expected to be approved for market by the second half of 2025 [5][6]. Company Overview - The latest closing price of the company's stock is 14.08 yuan, with a total market capitalization of 3.9 billion yuan [3]. - The company has a total share capital of 274 million shares, with 180 million shares in circulation [3]. - The company has a debt-to-asset ratio of 40.1% and a current P/E ratio of -74.11 [3]. Financial Forecast and Investment Suggestions - Revenue projections for the company are 72 million yuan in 2024, 84 million yuan in 2025, and 162 million yuan in 2026, with corresponding net losses of 47 million yuan, 54 million yuan, and 30 million yuan respectively [6][9]. - The expected price-to-sales ratios are 54x for 2024, 46x for 2025, and 24x for 2026, indicating potential growth as the company moves towards profitability [6].